Skip to main content

Table 2 Associations between isoform expression levels of APOBEC3A and APOBEC3B and germline APOBEC3A/B deletion

From: Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types

Cancer typea uc003awn uc011aoc uc011awo
Beta P Beta P Beta P
bladder 1.52 4.5 × 10− 4 −1.31 2.9 × 10−7 3.42 2.2 × 10− 39
breast 0.92 5.1 × 10− 4 − 0.71 3.0 × 10− 8 3.03 6.9 × 10− 66
cervical 1.44 0.06 −2.79 2.6 × 10− 10 2.67 5.5 × 10− 11
lungb 0.28 0.52 −1.35 2.6 × 10− 13 2.33 2.1 × 10− 12
lungc 0.55 0.51 − 3.60 9.1 × 10− 16 1.08 0.02
head and neck 0.86 0.06 −5.74 3.8 × 10− 65 2.63 6.3 × 10− 17
stomach 1.05 0.23 −0.25 0.37 3.01 8.0 × 10− 6
pancreas −0.14 0.91 −1.00 0.11 0.95 0.14
thyroid 0.90 4.5 × 10−3 −0.38 9.2 × 10−5 2.13 2.2 × 10−22
kidney 0.43 0.37 0.02 0.87 2.26 1.0 × 10−8
  1. a” Sample size for each cancer type: bladder (N = 286), breast (N = 734), cervical (N = 133), lung adenocarcinoma (N = 363), lung squamous carcinoma (N = 85), head and neck (N = 323), stomach (N = 66), pancreas (N = 90), thyroid (N = 333), kidney (N = 143). “b” and “c” refers to lung adenocarcinoma and lung squamous carcinoma, respectively. A univariate regression analysis was constructed to include APOBEC-mutational signature as dependent variables and expression levels as the independent variable for each isoform of each cancer type. The significance level at P = 0.005, corresponding to a threshold with a Bonferroni-correction of P = 0.05, given 10 tests